Evidence map›Paper›PMID 29674514›Full record

ReviewArchives of disease in childhood2018

Pharmacokinetic studies in children: recommendations for practice and research.

Charlotte I S Barker, Joseph F Standing, Lauren E Kelly, Lauren Hanly Faught, Allison C Needham, Michael J Rieder, Saskia N de Wildt, Martin Offringa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archives of disease in childhood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Optimizing Pediatric Drug Therapy: Pediatric Pharmacokinetics and Administration Routes.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
    Article
  10. Feasibility of vancomycin AUCFrontiers in pharmacology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charlotte I S BarkerInfection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-6757-5867
Joseph F StandingInfection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Lauren E KellyDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-7567-0816
Lauren Hanly FaughtDepartments of Paediatrics, Physiology and Pharmacology and Medicine, Western University, London, Ontario, Canada.
Allison C NeedhamChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Michael J RiederDepartments of Paediatrics, Physiology and Pharmacology and Medicine, Western University, London, Ontario, Canada.
Saskia N de WildtDepartment of Pharmacology and Toxicology, Radboud University, Nijmegen, The Netherlands.
Martin OffringaChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.

Funding

Department of Health ACF-2016-18-016Medical Research Council G1002305Medical Research Council M008665
6 · The paper itself

Abstract

Optimising the dosing of medicines for neonates and children remains a challenge. The importance of pharmacokinetic (PK) and pharmacodynamic (PD) research is recognised both in medicines regulation and paediatric clinical pharmacology, yet there remain barriers to undertaking high-quality PK and PD studies. While these studies are essential in understanding the dose-concentration-effect relationship and should underpin dosing recommendations, this review examines how challenges affecting the design and conduct of paediatric pharmacological studies can be overcome using targeted pharmacometric strategies. Model-based approaches confer benefits at all stages of the drug life-cycle, from identifying the first dose to be used in children, to clinical trial design, and optimising the dosing regimens of older, off-patent medications. To benefit patients, strategies to ensure that new PK, PD and trial data are incorporated into evidence-based dosing recommendations are needed. This review summarises practical strategies to address current challenges, particularly the use of model-based (pharmacometric) approaches in study design and analysis. Recommendations for practice and directions for future paediatric pharmacological research are given, based on current literature and our joint international experience. Success of PK research in children requires a robust infrastructure, with sustainable funding mechanisms at its core, supported by political and regulatory initiatives, and international collaborations. There is a unique opportunity to advance paediatric medicines research at an unprecedented pace, bringing the age of evidence-based paediatric pharmacotherapy into sight.

Indexed as

Models, BiologicalPharmacokineticsAgingBiomedical ResearchChildDose-Response Relationship, DrugEvidence-Based MedicineHumansResearch DesignSpecimen Handlingdosingneonatologypaediatricspharmacologypharmacometrics

Identifiers

PMID29674514
PMCPMC6047150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.